Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Table 2 Microwave ablation parameters after camrelizumab plus apatinib and hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma

Parameters	MWA (n = 95)
Ablation of residual tumor activity	63 (66.3)
Ablation of recurrent tumor	32 (33.7)
Maximum tumor diameter (cm)
≤ 5	58 (61.1)
> 5	37 (38.2)
No. of tumor
Single	74 (77.9)
Multiple	21 (22.1)
Extrahepatic metastasis before MWA	65 (68.4)
Ablation of tumor type number
1	73 (76.8)
2	19 (20)
> 2	3 (3.2)
Ablation of liver tumor	92 (96.8)
Ablation of lung tumor	13 (13.7)
Ablation of adrenal gland tumor	3 (3.2)
Ablation of breast tumor	1 (1.1)
Hepatic tumors
Ablative duration (minute)	26
Ablative power (W)	55.8 ± 6
Ablative sessions	2
Ablative points	4
Lung tumors
Ablative duration (minute)	14
Ablative power (W)	50.2 ± 3.4
Ablative sessions	1
Ablative points	2
Adrenal gland tumors
Ablative duration (minute)	20
Ablative power (W)	45.6 ± 4.2
Ablative sessions	1
Ablative points	1
Breast tumors
Ablative duration (minute)	16
Ablative power (W)	50
Ablative sessions	1
Ablative points	2
The response to HAIC
CR	8 (8.4)
PR	78 (82.1)
SD	9 (9.5)
Complete ablation of hepatic tumors	57 (60)
Complete ablation of all tumors	34 (35.8)
Recurrence after MWA	57 (60)
Combination of radiotherapy	8 (8.4)

Data are number of patients; data in parentheses are percentage unless otherwise indicated. Data in bracket was percent of patients. HCC: Hepatocellular carcinoma; MWA: Microwave ablation; HAIC: Hepatic arterial infusion chemotherapy; CR: Complete response; PR: Partial response; SD: Stable disease.